2021
DOI: 10.5817/csf2021-4-136
|View full text |Cite
|
Sign up to set email alerts
|

<sup>68</sup>Ga-DOTATOC

Abstract: The radiopharmaceutical 68Ga-DOTATOC represents the latest radiopharmaceutical in the diagnosis of a neuroendocrine tumor with somatostatin receptor overexpression. Technological and economic difficulties of preparing and quality control of the radiopharmaceutical limit its use to specialised departments. Background of the department with rich experience with radiopharmaceuticals for positron emission tomography allows handling more difficult 68Ga-radiopharmacy and may increase and improve the care of oncology… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 6 publications
0
1
0
Order By: Relevance
“…SSTR imaging plays a central role in the management of NETs [ 3 ]. Initially confined to single photon emitting radiopharmaceuticals with 111In-Pentetreotide, SSTR imaging possibilities have been extended to positron emitters with the arrival of 68 Ga-labeled peptides, notably 68 Ga-DOTATATE and 68 Ga-DOTATOC [ 4 , 5 ]. In addition to tumor uptake, several physiological uptakes have been described.…”
Section: Introductionmentioning
confidence: 99%
“…SSTR imaging plays a central role in the management of NETs [ 3 ]. Initially confined to single photon emitting radiopharmaceuticals with 111In-Pentetreotide, SSTR imaging possibilities have been extended to positron emitters with the arrival of 68 Ga-labeled peptides, notably 68 Ga-DOTATATE and 68 Ga-DOTATOC [ 4 , 5 ]. In addition to tumor uptake, several physiological uptakes have been described.…”
Section: Introductionmentioning
confidence: 99%